Loading
Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade.
Alberto Bardelli led the 2012 Nature study showing that KRAS mutations emerge in the blood of colorectal cancer patients months before radiological progression on cetuximab or panitumumab, one of the first demonstrations of liquid biopsy for tracking resistance, and later showed these clones decay when anti-EGFR therapy is stopped, the basis for rechallenge strategies. His laboratory also showed that mismatch repair inactivation increases immunotherapy sensitivity.
The first demonstration that HER2 is actionable in colorectal cancer, and the trial that defined the colorectal-specific HER2 scoring criteria every later trial has used.
It made acquired resistance a measurable, plasma-readable event, and it is the origin of anti-EGFR rechallenge strategies guided by ctDNA clearance of the resistant clone.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Colorectal cancer and the tags ctdna, colorectal.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer and the tag colorectal.
Shares EGFR, KRAS, Liquid biopsy (ctDNA), Colorectal cancer and the tag colorectal.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer and the tag colorectal.
Shares EGFR, KRAS, Liquid biopsy (ctDNA), Colorectal cancer and the tag colorectal.
Shares EGFR, KRAS, Colorectal cancer and the tag colorectal.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Colorectal cancer and the tag colorectal.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna.